Cancer Research Institute
https://www.cancerresearch.org/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cancer Research Institute
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.
MedImmune Turns To Venture Philanthropy For Cancer ImmunoRx Combination Trials
MedImmune and two non-profit research organizations are collaborating on clinical trials that explore the tricky world of combinations of novel cancer immunotherapies, including three MedImmune compounds in different stages of development.
MedImmune Turns To Venture Philanthropy For Cancer ImmunoRx Combination Trials
MedImmune and two non-profit research organizations are collaborating on clinical trials that explore the tricky world of combinations of novel cancer immunotherapies, including three MedImmune compounds in different stages of development.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice